Drugs for diabetes: part 2 sulphonylureas

Br J Cardiol 2010;17:279–82 Leave a comment
Click any image to enlarge
Authors:

Sulphonylureas are well established in the treatment of type 2 diabetes mellitus. They are effective in improving glycaemic control and preventing microvascular complications. Side effects that can restrict use include hypoglycaemia and weight gain. Although there is no clear evidence for reduction of cardiovascular disease from randomised-controlled trials, follow-up data from the United Kingdom Prospective Diabetes Study (UKPDS) shows reduced cardiovascular risk. Concerns about sulphonylureas causing inhibition of ischaemic preconditioning are relevant in primary angioplasty, but there is a lack of clear evidence, with a need for randomised-controlled trials to investigate this further.

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.


You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT